ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 33 filers reported holding ASCENDIS PHARMA A/S in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $33,137,000 | +2018.7% | 251,900 | +1713.7% | 8.24% | +1472.1% |
| Q1 2020 | $1,564,000 | -85.3% | 13,889 | -84.6% | 0.52% | -81.7% |
| Q1 2019 | $10,631,000 | +370.2% | 90,325 | -19.7% | 2.87% | +84.1% |
| Q3 2016 | $2,261,000 | -15.9% | 112,497 | -44.5% | 1.56% | +13.5% |
| Q2 2016 | $2,687,000 | -22.6% | 202,520 | +8.2% | 1.37% | +8.0% |
| Q1 2016 | $3,473,000 | -33.4% | 187,220 | -34.3% | 1.27% | -45.0% |
| Q4 2015 | $5,217,000 | +9.3% | 284,785 | +5.6% | 2.31% | -29.4% |
| Q3 2015 | $4,775,000 | +33.3% | 269,785 | +33.2% | 3.27% | +85.0% |
| Q2 2015 | $3,581,000 | – | 202,525 | – | 1.77% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |